Condition

MASH - Metabolic Dysfunction-Associated Steatohepatitis clinical trials and research

• 19Clinical trials
• 23Countries

Newest MASH - Metabolic Dysfunction-Associated Steatohepatitis clinical trials

All recruiting trials (19)

• Rezdiffra with diabetes and pioglitazone or dapagliflozin in adults with MASH and F2-F3 fibrosis

  This study tests whether Rezdiffra (resmetirom) can be safely used together with common diabetes medicines in adults with MASH and moderate to advanced liver fibrosis.

  Recruiting at 3 sites Phase 4 Madrigal Pharmaceuticals, Inc. · Chandler, Arizona and 15 other locations · NCT07848191

• Resmetirom for MASH with HFpEF in adults

  This study tests whether resmetirom can be given safely and show liver-related effects in adults with MASH and heart failure with preserved ejection fraction over 24 weeks.

  Recruiting at 5 sites Phase 1 Madrigal Pharmaceuticals, Inc. · Peoria, Arizona and 4 other locations · NCT07830758

• MWN105 injection in overweight or obese adults you may join

  This early-phase trial tests whether MWN105 is safe and tolerable in overweight or obese adults in China, using a placebo comparison.

  Recruiting Phase 1 Shanghai Minwei Biotechnology Co., Ltd · Kunming, Yunnan · NCT07803809

• Resmetirom in children and teens with MASH

  This study tests how safe resmetirom is and how it acts in the body of kids aged 6 to 17 who have MASH with liver fibrosis.

  Recruiting Phase 2 Madrigal Pharmaceuticals, Inc. · Indianapolis, Indiana · NCT07763015

• Liver Inflammation Index test for MASH in adults with T2DM and MAFLD

  This study tests a Liver Inflammation Index to see if it can identify MASH in adults who have both type 2 diabetes and MAFLD.

  Recruiting at 22 sites The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Bengbu, Anhui and 21 other locations · NCT07632677

• HSK31679 in MASH: a phase 3 test for safety and liver improvement

  This phase 3 trial tests whether HSK31679 helps people with MASH compared to a placebo.

  Recruiting Phase 3 Haisco Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality · NCT07581951

• Rezdiffra pregnancy and breastfeeding registry for women with NASH

  This registry collects information about pregnancy and infant health for women with NASH who were exposed to Rezdiffra during pregnancy or while breastfeeding.

  Recruiting Madrigal Pharmaceuticals, Inc. · West Conshohocken, Pennsylvania · NCT07541469

• HU6 compared with placebo for adults with MASH

  This study tests whether HU6 is safe and can reduce liver fat in adults with metabolic dysfunction-associated steatohepatitis (MASH).

  Recruiting at 31 sites Phase 2 Rivus Pharmaceuticals, Inc. · Chandler, Arizona and 30 other locations · NCT07491458

• Exercise for an Aging Liver

  This study tests whether a supervised 12-week exercise program can reduce liver fat, inflammation, and fibrosis in adults with MASLD or at-risk MASH, comparing younger and older adults and different disease severities.

  Recruiting Consorcio Centro de Investigación Biomédica en Red (CIBER) · Madrid, Madrid · NCT07467512

• Testing molecular markers to identify high-risk colorectal polyps in people with MASH

  This project will test whether specific gene-expression markers in polyp tissue and blood can identify high-risk colorectal polyps in adults with metabolic dysfunction-associated steatohepatitis (MASH) who are having colonoscopic polyp removal.

  Recruiting Shanghai East Hospital · Shanghai, Shanghai Municipality · NCT07463287

• TGM-312-SC01 injections for healthy adults and people with MASH

  This trial tests single increasing doses in healthy volunteers and repeated increasing doses in adults with MASH to see if TGM-312-SC01 is safe and how the body processes it.

  Recruiting Phase 1/2 Tangram Therapeutics Plc · London · NCT07427680

• Resmetirom for post-liver transplant MASH with moderate to advanced fibrosis

  This trial will test resmetirom versus placebo to see if it reduces liver fat and improves fibrosis in people who developed MASH after a liver transplant.

  Recruiting at 12 sites Phase 2 Madrigal Pharmaceuticals, Inc. · La Jolla, California and 16 other locations · NCT07335601

• Chiglitazar for MASH and Type 2 Diabetes

  This trial tests whether chiglitazar can help adults with MASH and type 2 diabetes when added to standard vitamins and liver-supporting therapy.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Beijing, Beijing Municipality and 16 other locations · NCT07303803

• Resmetirom for MASH in Pakistani patients

  This trial will test whether resmetirom is safe and helps adults in Pakistan with MASH who also have metabolic risk factors.

  Recruiting Phase 4 Nabiqasim Industries (Pvt) Ltd · Rawalpindi, Punjab Province · NCT07249788

• Does fructose worsen metabolism and liver inflammation in people with MASH?

  This test looks at whether short-term dietary fructose changes metabolism and increases liver inflammation in people aged 45–65 with MASH, people with simple fatty liver (steatosis), and healthy controls.

  Recruiting at 2 sites Queen Mary University of London · London and 1 other locations · NCT07013916

• Time-restricted eating plus a healthy diet for people with liver cancer

  This trial will try an 8–10 hour time-restricted eating plan together with targeted healthy food changes for overweight adults with early-to-intermediate liver cancer who are having liver-directed therapy.

  Recruiting University of California, San Diego · La Jolla, California · NCT06824974

• Ultraportable Hepatoscope ultrasound for measuring liver fat in MASLD/MASH

  The Hepatoscope device will be tested to see if it can measure liver fat accurately in adults with MASLD/MASH compared with MRI-PDFF.

  Recruiting at 2 sites E-Scopics · Angers and 2 other locations · NCT06661655

• Digoxin for NASH with stage 2–3 fibrosis

  This trial will see if taking once-daily digoxin helps clear NASH and reduce liver scarring in adults with biopsy-confirmed NASH and stage 2–3 fibrosis.

  Recruiting at 2 sites Phase 2 Yale University · New Haven, Connecticut and 1 other locations · NCT06588699

• Evaluating efruxifermin for patients with compensated cirrhosis due to NASH/MASH

  This study is testing a new medication called efruxifermin to see if it can improve liver health in people with compensated cirrhosis caused by NASH or MASH.

  Recruiting at 322 sites Phase 3 Akero Therapeutics, Inc · Birmingham, Alabama and 344 other locations · NCT06528314

Related topics

Quick answers

How many MASH - Metabolic Dysfunction-Associated Steatohepatitis clinical trials are recruiting right now?

19, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 23 countries. The most sites are in United States (9 trials), China (5 trials), United Kingdom (3 trials), Spain (2 trials), Canada (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 1: 2, Phase 4: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →